These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28977728)

  • 1. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
    Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
    BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
    Chen Z; Chen N; Shen P; Gong J; Li X; Zhao T; Liao B; Liu L; Liu Z; Zhang X; Liu J; Peng Z; Chen X; Xu M; Gui H; Zhang P; Wei Q; Zhou Q; Zeng H
    Prostate; 2015 Sep; 75(12):1247-54. PubMed ID: 25917338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
    Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
    Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
    Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
    Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
    Russell DH; Epstein JI
    Am J Surg Pathol; 2022 Feb; 46(2):233-240. PubMed ID: 34619708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
    Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
    Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.
    Lawrence MG; Pook DW; Wang H; Porter LH; Frydenberg M; Kourambas J; Appu S; Poole C; Beardsley EK; Ryan A; Norden S; Papargiris MM; Risbridger GP; Taylor RA
    Prostate; 2015 Sep; 75(13):1475-83. PubMed ID: 26177841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
    Shah RB; Yoon J; Liu G; Tian W
    Histopathology; 2017 Nov; 71(5):693-702. PubMed ID: 28570007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
    Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
    Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
    Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
    Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rise in serum folate after androgen deprivation associated with worse prostate cancer-specific survival.
    Liss MA; Ashcraft K; Satsangi A; Bacich D
    Urol Oncol; 2020 Aug; 38(8):682.e21-682.e27. PubMed ID: 32444177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
    Naito Y; Kato M; Kawanishi H; Yamamoto A; Sakamoto F; Hirabayashi H; Kobayashi M; Matsukawa Y; Kimura T; Araki H; Nishikimi T; Kondo A; Yoshino Y; Hashimoto Y; Nakano Y; Tsuzuki T
    Prostate; 2023 Mar; 83(4):307-315. PubMed ID: 36420892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?
    Bonkhoff H; Wheeler TM; van der Kwast TH; Magi-Galluzzi C; Montironi R; Cohen RJ
    Prostate; 2013 Mar; 73(4):442-8. PubMed ID: 22949099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.